These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 8933168)

  • 1. Effects of interferon-alpha treatment on neutrophil oxidative metabolism, lymphocyte proliferation and monocyte HLA class I antigen expression in patients with chronic hepatitis C.
    Piazzolla G; Giannelli G; Antonelli G; Tortorella C; Jirillo E; Schiraldi O; Antonaci S
    Immunopharmacol Immunotoxicol; 1996 Nov; 18(4):529-48. PubMed ID: 8933168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological effects following administration of interferon-alpha in patients with chronic hepatitis C virus (cHCV) infection.
    Jirillo E; Greco B; Caradonna L; Satalino R; Amati L; Cozzolongo R; Cuppone R; Manghisi OG
    Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):355-74. PubMed ID: 8872490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
    Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
    J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced alloreactive T-cell activation after alcohol intake is due to impaired monocyte accessory cell function and correlates with elevated IL-10, IL-13, and decreased IFNgamma levels.
    Szabo G; Mandrekar P; Dolganiuc A; Catalano D; Kodys K
    Alcohol Clin Exp Res; 2001 Dec; 25(12):1766-72. PubMed ID: 11781510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids.
    Rhodes J; Ivanyi J; Cozens P
    Eur J Immunol; 1986 Apr; 16(4):370-5. PubMed ID: 2422040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of hepatitis C virus-specific T cell responses and cytokine production in chronic hepatitis C patients treated with high doses of interferon-alpha.
    Alvarado Esquivel C; Elewaut A; Philippé J; Elewaut AE; Desombere I; Maertens G; Leroux-Roels G
    Rev Invest Clin; 2002; 54(1):41-50. PubMed ID: 11995406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-alpha therapy and anti-human leukocyte antigen antibodies in hepatitis C virus-positive patient: case report.
    Cervelli C; Fontecchio G; Fioroni MA; Azzarone R; Battistoni C; Maccarone D; Pisani F; Papola F
    Transplant Proc; 2007; 39(6):2040-1. PubMed ID: 17692687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy.
    Sakaida I; Nagatomi A; Hironaka K; Uchida K; Okita K
    Am J Gastroenterol; 1999 Feb; 94(2):489-96. PubMed ID: 10022652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
    Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
    Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up after successful interferon therapy of acute hepatitis C.
    Wiegand J; Jäckel E; Cornberg M; Hinrichsen H; Dietrich M; Kroeger J; Fritsch WP; Kubitschke A; Aslan N; Tillmann HL; Manns MP; Wedemeyer H
    Hepatology; 2004 Jul; 40(1):98-107. PubMed ID: 15239091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum hyaluronate predicts response to interferon-alpha therapy in patients with chronic hepatitis C.
    Ueno T; Inuzuka S; Sata M; Koh H; Tamaki S; Kin M; Sugawara H; Sakata R; Torimura T; Tanikawa K
    Hepatogastroenterology; 1995; 42(5):522-7. PubMed ID: 8751209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of glioma cells to interferon-gamma: increase in class II RNA, protein and mixed lymphocyte reaction-stimulating ability.
    Takiguchi M; Ting JP; Buessow SC; Boyer C; Gillespie Y; Frelinger JA
    Eur J Immunol; 1985 Aug; 15(8):809-14. PubMed ID: 2411569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Types of human leukocyte antigen and decrease in HCV core antigen in serum for predicting efficacy of interferon-Alpha in patients with chronic hepatitis C: analysis by a prospective study.
    Muto H; Tanaka E; Matsumoto A; Yoshizawa K; Kiyosawa K;
    J Gastroenterol; 2004 Jul; 39(7):674-80. PubMed ID: 15293139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymphoproliferative responses to hepatitis C virus core, E1, E2, and NS3 in patients with chronic hepatitis C infection treated with interferon alfa.
    Leroux-Roels G; Esquivel CA; DeLeys R; Stuyver L; Elewaut A; Philippé J; Desombere I; Paradijs J; Maertens G
    Hepatology; 1996 Jan; 23(1):8-16. PubMed ID: 8550052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The induction of class I HLA by interferon-alpha is independent of the cell cycle, but the expression is enhanced by a G1/S block.
    Erusalimsky JD; Gilmore D; Milstein C
    Eur J Immunol; 1987 May; 17(5):623-8. PubMed ID: 3108014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell growth factor-induced and alpha-interferon-inhibited proliferation of hairy cells coincides with modulation of cell surface antigens.
    Gamliel H; Brownstein BH; Gurfel D; Wu SH; Rosner MC; Golomb HM
    Cancer Res; 1990 Jul; 50(13):4111-20. PubMed ID: 2354460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoresponsiveness in chronic hepatitis C patients: correlation between tissue and serum findings.
    Piazzolla G; Tortorella C; Fiore G; Serrone M; Caccetta L; Jirillo E; Schiraldi O; Antonaci S
    Immunopharmacol Immunotoxicol; 1998 Aug; 20(3):337-54. PubMed ID: 9736440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Serum variations of 2 markers of fibrogenesis in chronic hepatitis C treated with alpha interferon].
    Soresi M; Bascone F; Agate V; Carroccio A; Barresi E; Cartabellotta A; Aragona F; Montalto G
    Recenti Prog Med; 1997 Feb; 88(2):73-6. PubMed ID: 9148370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Suzuki F; Akuta N; Someya T; Hosaka T; Kobayashi M; Kumada H
    J Gastroenterol; 2004; 39(5):455-60. PubMed ID: 15175944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.